Reverse Transcriptase Inhibitors
1 drugsAbout Reverse Transcriptase
Reverse transcriptase is an enzyme essential for retrovirus replication, catalyzing DNA synthesis from an RNA template. It plays a crucial role in the life cycle of viruses like HIV, making it a key target for antiviral therapies.
Inhibiting reverse transcriptase can effectively disrupt viral replication and slow disease progression. Currently, there is no genetic evidence directly linking reverse transcriptase to specific human diseases.
GENVOYA is the only FDA-approved drug targeting reverse transcriptase, developed by Gilead Sciences. It is a small molecule approved in 2015 for a single indication within the 'Other' therapeutic area.
Top Reverse Transcriptase Drugs
Gilead Sciences is the only company with an approved drug targeting reverse transcriptase.
The market is highly concentrated, indicating potential entry barriers or a lack of competitive innovation.
Reverse Transcriptase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Reverse Transcriptase, using small molecule modality.
Explore alternative modalities like antibodies or gene therapies to differentiate from existing treatments.
Reverse Transcriptase Clinical Trials 63 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Reverse Transcriptase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 34 | 30 | 3 | 1 | 91% |
| Phase 2 | 5 | 2 | 1 | 2 | 67% |
| Phase 3 | 7 | 6 | 1 | 0 | 86% |
| Phase 4 | 17 | 9 | 3 | 5 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Reverse Transcriptase Drug Approval Timeline (2015 - 2015)
The first and only drug, GENVOYA, was approved in 2015.
The approval timeline suggests a potentially saturated market or challenges in developing new therapies for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 43 (16 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Reverse Transcriptase. A trial counts if an approved drug acting on Reverse Transcriptase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.